1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Florida’s Drug Importation Plan Is Missing Cost Savings, Supply Chain Data, FDA Says

 
• By Brenda Sandburg

Florida says new questions about its proposal show the lengths FDA will go to avoid approving it. FDA extends its deadline for acting on the application, which is the most detailed of four submitted to the agency.

Drug costs
FDA wants more information on cost savings under Florida's proposed prescription drug importation program • Source: Shutterstock (Shutterstock)

The US Food and Drug Administration is extending its deadline to act on Florida’s proposal to import prescription drugs as it reviews additional information it requested on a host of issues, including cost savings from the program and how the drug supply chain will be secured.

The agency expects to issue a decision on whether to authorize Florida’s proposal within 60 days after reviewing information it requested from the state in August if the information adequately addresses issues it raised. The FDA set the new timeline in a 20 October

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Market Access

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.